cohbar.JPG
CohBar to Present at the BIO 2021 Digital Conference
June 10, 2021 09:00 ET | CohBar, Inc.
MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
cohbar.JPG
CohBar Reports First Quarter 2021 Financial Results and Provides Business Update
May 17, 2021 16:02 ET | CohBar, Inc.
MENLO PARK, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
cohbar.JPG
CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021
May 03, 2021 09:00 ET | CohBar, Inc.
MENLO PARK, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
cohbar.JPG
CohBar Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director
April 27, 2021 08:30 ET | CohBar, Inc.
MENLO PARK, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
cohbar.JPG
CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
April 21, 2021 09:00 ET | CohBar, Inc.
MENLO PARK, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
cohbar.JPG
CohBar to Present at the Mitochondria-Targeted Drug Development Summit
April 14, 2021 09:00 ET | CohBar, Inc.
MENLO PARK, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
cohbar.JPG
CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update
March 30, 2021 16:02 ET | CohBar, Inc.
MENLO PARK, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
cohbar.JPG
CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
March 29, 2021 09:00 ET | CohBar, Inc.
MENLO PARK, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
cohbar.JPG
CohBar to Announce 2020 Fourth Quarter Financial Results and Provide Business Update on March 30, 2021
March 16, 2021 16:05 ET | CohBar, Inc.
MENLO PARK, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
cohbar.JPG
CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases
March 16, 2021 09:00 ET | CohBar, Inc.
MENLO PARK, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...